Literature DB >> 26358169

NFAT inhibitor tributylhexadecylphosphoniumbromide, ameliorates high fructose induced insulin resistance and nephropathy.

Maitri Sanghavi1, Malek Vajir2, Sandeep Kumar3, Kulbhushan Tikoo4.   

Abstract

High fructose diet (HFrD)-induced insulin resistance (IR) has been reported to be associated with an increase in albuminuria, glomerular hypertrophy and inflammation in kidney. However, the molecular mechanisms associated with high fructose-induced IR and renal dysfunction are still unclear. In the present study, we have investigated the role of nuclear factor of activated T-cell (NFAT) and its inhibitor, Tributylhexadecylphosphoniumbromide (THPB) in high fructose-induced IR and renal injury. NFAT inhibition by THPB treatment significantly improved HFrD-induced insulin resistance. Treatment with THPB markedly reduced high fructose diet-induced protein expression of NFATc4, PTEN and also alleviated expression of inflammatory markers in kidneys of HFrD rats. Further, THPB treatment not only improved acute ANG II responses but also repressed the processes of renal fibrosis, ECM accumulation, foot process effacement and renal apoptosis in HFrD rats. Taken together, we for the first time provide evidence that HFrD -induced insulin resistance and renal injury is associated with dysregulated NFATc4/PTEN signalling and THPB prevents this dysregulation through inhibition of NFATc4. Thus, targeting NFATc4 can be a novel therapeutic approach for preventing HFrD induced- IR and renal injury.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Diabetic nephropathy; Insulin resistance; NFATc4; THPB

Mesh:

Substances:

Year:  2015        PMID: 26358169     DOI: 10.1016/j.cbi.2015.09.002

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  1 in total

1.  Inhibition of PTEN activity aggravates cisplatin-induced acute kidney injury.

Authors:  Jun Zhou; Youling Fan; Simin Tang; Huiping Wu; Jiying Zhong; Zhengxing Huang; Chengxiang Yang; Hongtao Chen
Journal:  Oncotarget       Date:  2017-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.